Lower Risk of Growth-Related Side Effects: Because it does not appear to raise IGF-1 significantly, the peptide may carry fewer systemic risks than traditional growth hormone therapies
It is not appropriate for anyone pregnant or breastfeeding, those with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, or certain other medical conditions all of which we screen for at your initiation visit
Adjusting to a new formulation may take several weeks
They actually complement each other rather than compete
Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28,29,30]
2020 About G